Researchers have identified acute myeloid leukemia as a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard ...
Oct 14, 2020
0
9
Though cancer immunotherapy has become a promising standard-of-care treatment—and in some cases, perhaps a cure—for a wide variety of different cancers, it doesn't work for everyone, and researchers have increasingly ...
Oct 2, 2020
0
95
Breast cancer is the most frequent neoplasm among women, impacting 2.1 million women per year. It also has a high risk for intracranial spread. Researchers estimate that up to 30% of all patients with cancer will eventually ...
Sep 28, 2020
0
0
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of ...
Sep 22, 2020
0
30
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
Sep 19, 2020
0
7
Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.
Sep 15, 2020
0
8
A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence (NICE).
Sep 7, 2020
0
3
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be a step closer after three research groups presented safety and efficacy data at the Digital International Liver Congress ...
Aug 28, 2020
0
2
A recent finding by researchers at the BC Cancer Research Institute and the University of British Columbia (UBC) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.
Aug 27, 2020
0
4
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by ...
Aug 13, 2020
0
5
